An Indian multicentric open label prospective post marketing surveillance study of bevacizumab in the front line management of advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in real-life clinical practice

Trial Profile

An Indian multicentric open label prospective post marketing surveillance study of bevacizumab in the front line management of advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in real-life clinical practice

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2016 Planned End Date changed from 1 Jan 2020 to 1 Mar 2021.
    • 01 Nov 2016 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2021.
    • 01 Nov 2016 Planned initiation date changed from 1 Feb 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top